- Neurothera Labs (TSXV:NTLX) has been granted a US patent for combining antimicrobials and cannabinoids designed to fortify antibiotics against resistant bacterial strains
- Neurothera, a majority-owned subsidiary of SciSparc (NASDAQ:SPRC), is a clinical-stage pharmaceutical company developing therapeutics for central nervous system disorders and other underserved health conditions
- Neurothera stock last traded at C$0.20
Clinical-stage biotech company Neurothera Labs (TSXV:NTLX) has been granted a US patent for combining antimicrobials and cannabinoids designed to fortify antibiotics against resistant bacterial strains.
The technology, supported by a much broader patent portfolio, showed enhanced antimicrobial activity in pre-clinical studies, suggesting the potential to restore the utility of antibiotics that proved ineffective on their own, particularly against resistant Gram-positive pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA).
According to Monday’s news release, MRSA remains a global concern, having developed resistance to multiple antibiotic classes, leading to approximately 130,000 deaths in 2021, more than double the 57,000 in 2019, representing the largest mortality increase among resistant pathogens.
With major players eschewing antibiotic innovation because of bacterial resistance and its hit to profitability, Neurothena believes its solution has the potential to create meaningful change, decreasing the more than one million deaths per year attributable to bacterial antimicrobial resistance, according to a report from the World Health Organization, while garnering a growing share in the US$58 billion global antibiotics market.
About Neurothera Labs
Neurothera Labs, a majority-owned subsidiary of SciSparc (NASDAQ:SPRC), is a clinical-stage pharmaceutical company developing therapeutics for central nervous system disorders and other underserved health conditions.
Neurothera stock (TSXV:NTLX) last traded at C$0.20.
Join the discussion: Find out what investors are saying about this cannabis pharmaceutical stock on the Neurothera Labs Inc. Bullboard and make sure to explore the rest of Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
For full disclaimer information, please click here.
